土三七导致肝窦阻塞综合征伴门静脉血栓形成1例报道与文献复习

doi:10.3969/j.issn.1672-5069.2025.06.039

Abstract

Abstract: We reported a case of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome (PA-HSOS) complicated by portal vein thrombosis (PVT) here, and successfully dealt with transjugular intrahepatic portosystemic shunt (TIPS). The patient had a clear history of ingesting PA-containing herbal medicine (Gynura segetum, commonly known as Tusanqi). Initial anticoagulation therapy proved ineffective, but significant symptomatic improvement was observed following TIPS intervention. This report includes a literature review with an overview and analysis of the pathophysiology, clinical features, diagnostic strategies, and therapeutic options for HSOS complicated by PVT, aiming to enhance clinicians’ understanding and management of this rare but serious entity.

Key words: Hepatic sinusoidal obstruction syndrome, Pyrrolidine alkaloid, Portal vein thrombosis, Case report

Liang Shengkai, Yin Xiaochun, Zhang Feng, et al. Hepatic sinusoidal obstruction syndrome induced by gynura segetum with portal vein thrombosis: A case report and literature review[J]. Journal of Practical Hepatology, 2025, 28(6): 954-956.

References

[1] Elkrief L, Hernandez-Gea V, Senzolo M, et al. Portal vein thrombosis: diagnosis, management, and endpoints for future clinical studies. Lancet Gastroenterol Hepatol, 2024, 9(9): 859-883.
[2] Bagot C N, Arya R. Virchow and his triad: a question of attribution. Bri J Haematol, 2008, 143(2): 180-190.
[3] Ogren M, Bergqvist D, Björck M, et al. Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J Gastroenterol, 2006, 12(13): 2115-2119.
[4] 赵剑波, 谭卿. 非肝硬化性门静脉高压症研究进展. 实用肝脏病杂志, 2021, 24(5): 613-616.
[5] Edgar J A, Molyneux R J, Colegate S M. Pyrrolizidine alkaloids: Potential role in the etiology of cancers, pulmonary hypertension, congenital anomalies, and liver disease. Chem Res Toxicol, 2015, 28(1): 4-20.
[6] Xu J, Wang W, Yang X, et al. Pyrrolizidine alkaloids: An update on their metabolism and hepatotoxicity mechanism. Liver Res, 2019, 3(3): 176-184.
[7] Garcia-Tsao G, Abraldes J G, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology (Baltimore, Md.), 2017, 65(1): 310-335.
[8] 中华医学会消化病学分会肝胆疾病学组. 肝硬化门静脉血栓管理专家共识(2020年,上海). 中华消化杂志, 2020, 40(11): 721-730.
[9] Garcia-Pagán J C, Valla D C. Primary Budd-Chiari syndrome. New Engl J Med, 2023, 388(14): 1307-1316.
[10] Tong Y, Zhang M, Qi Z, et al. Hepatic venous occlusion type of Budd-Chiari syndrome versus pyrrolizidine alkaloid-induced hepatic sinusoidal obstructive syndrome: A multi-center retrospective study. J Personal Med, 2023, 13(4): 603.
[11] Zhuge Y, Liu Y, Xie W, et al. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. J Gastroenterol Hepatoly, 2019, 34(4): 634-642.
[12] 张明. 肝硬化门静脉血栓形成诊治新进展. 实用肝脏病杂志, 2024, 27(1): 11-15.
[13] Loffredo L, Pastori D, Farcomeni A, et al. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: A systematic review and Meta-analysis. Gastroenterology, 2017, 153(2): 480-487,e1.
[14] Lyu Y, Qi X, He C, et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut, 2018, 67(12): 2156-2168.
[15] Lyu Y, Bai W, Li K, et al. Anticoagulation and transjugular intrahepatic oortosystemic shunt for the management of portal vein thrombosis in cirrhosis: A prospective observational study. Am J Gastroenterol, 2021, 116(7): 1447-1464.
[16] Han G, Qi X, He C, et al. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis. J Hepatol, 2011, 54(1): 78-88.
[17] 中华医学会消化病学分会肝胆疾病协作组. 吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见(2017年,南京). 临床肝胆病杂志, 2017, 33(9): 1627-1637.
[18] Wang X, Zhang W, Zhang M, et al. Development of a drum tower severity scoring (DTSS) system for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. Hepatol Int, 2022, 16(3): 669-679.
[19] Wu F, Yu J, Gan H, et al. Timing and efficacy of transjugular intrahepatic portosystemic shunt in patients with pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. Sci Rep, 2021, 11(1): 21743.

Hepatic sinusoidal obstruction syndrome induced by gynura segetum with portal vein thrombosis: A case report and literature review

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Yao Yu, Ning Bo. Pathogenesis,spontaneous recanalization and anticoagulation therapy in patients with liver cirrhosis and portal vein thrombosis [J]. Journal of Practical Hepatology, 2025, 28(6): 801-804.
[2]	Lu Tao, Li Jiaguo, Li Shiwei, et al. Risk factors influencing portal vein thrombosis after splenectomy and portoazygous devascularization in patients with hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2025, 28(6): 882-885.
[3]	Wang Chuang, Zhou Lin, Gao Huanhuan, et al. Predictive performance of thromboelastogram parameters and blood coagulation indexes for portal vein thrombosis in patients with liver cirrhosis after splenectomy [J]. Journal of Practical Hepatology, 2025, 28(5): 739-742.
[4]	Ding Wenjin, Fan Jiangao, Zeng Jing. A sophisticated case report of liver injury [J]. Journal of Practical Hepatology, 2025, 28(5): 792-793.
[5]	Cui Yeqi, Zhang Shibin. Classification and formation mechanism of portal vein thrombosis in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2025, 28(2): 161-164.
[6]	Tian Ruiyuan, Wei Chao, Li Yong. Effect of Yiqi Huoxue Tongluo compound intervention on portal vein recanalization in rats with surgery-induced portal vein thrombosis [J]. Journal of Practical Hepatology, 2025, 28(1): 24-27.
[7]	Zhou Lili, Shi Yiwen, Fan Jiaogao, et al. A young man with metabolic dysfunction-associated fatty liver disease-induced liver cirrhosis and ABCA1 mutation: a case report [J]. Journal of Practical Hepatology, 2024, 27(4): 638-640.
[8]	Wu Dahai, Liu Qilin, Lu Jiefu, et al. Changes of serum neutrophil extracellular trap markers in patients with hepatitis B liver cirrhosis complicated by portal vein thrombosis [J]. Journal of Practical Hepatology, 2024, 27(3): 394-397.
[9]	Jin Keke, Ding Huiguo. Risk and anticoagulation management of cirrhotic patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2024, 27(1): 3-6.
[10]	Zhang Ming. Portal vein thrombosis in cirrhotic patients: the states of the art [J]. Journal of Practical Hepatology, 2024, 27(1): 11-15.
[11]	Shi Cuicui, , Xu Zhengjie, Zhou Huiqing, et al.. Portal vein cavernous transformation caused by JAK2V617F mutation positive myeloproliferative tumor: a case report [J]. Journal of Practical Hepatology, 2023, 26(3): 443-444.
[12]	Shi Haitao, Lu Xiaolan. Portal vein thrombosis and hepatic arterio-portal fistula: a re-conceptualization of the diagnosis and treatment [J]. Journal of Practical Hepatology, 2023, 26(2): 160-163.
[13]	Zhu Haiyan, Fan Xiaotang. Nomogram model in predicting portal venous thrombosis in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(6): 848-852.
[14]	Li Ting,Mao Xiaorong, Zhang Xuemei, et al.. Comparison of incidence of portal vein thrombosis in cirrhotics with hypersplenism after undergoing splenectomy or TIPS [J]. Journal of Practical Hepatology, 2022, 25(5): 685-688.
[15]	Zhuge Yuzheng, Wang Xuan. Hepatic sinusoidal obstruction syndrome associated with pyrrolizidine alkaloids [J]. Journal of Practical Hepatology, 2021, 24(5): 617-620.